Open Orphan (LON: ORPH) shares are up 6% on Friday after the company announced that its subsidiary, hVIVO, has signed a “significant” contract with AIM ImmunoTech to test its antiviral candidate, Ampligen.
hVIVO will use both the human Rhinovirus HRV (common cold virus) and Influenza human challenge study models as part of a single study.
The study will be conducted by hVIVO with Philadelphia-based AIM ImmunoTech the sponsor of the Phase 2 human challenge trial, which is expected to commence in Q4.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
While there were no financial details provided, Open Orphan said it expects the majority of revenue from the contract to be recognised in the current financial year.
They also expect to sign more contracts in this area due to the increased international focus on respiratory and infectious diseases following the outbreak of COVID-19.
“We are delighted to commence work with AIM ImmunoTech, a leading immuno-pharma company, to test their product against both HRV and Influenza human challenge study models as part of a single study,” said Cathal Friel, Executive Chairman of Open Orphan.
“Fortunately, with our access to three challenge study clinics in London, we were able to find a small gap in our schedule later this year to slot this particular study in at short notice,” he added.
Open Orphan’s share price is currently trading at 26.5p, up 6%.
Should you invest in Open Orphan shares?
Open Orphan shares are traded on the London stock exchange’s AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. Find out why Open Orphan shares made it onto our list of the best AIM stocks to buy…
